KU Leuven and FIT Biotech Enter Into a Worldwide License Agreement
News Jul 30, 2013
KU Leuven and FIT Biotech have announced that they entered into a worldwide license and collaboration agreement for the development of novel immunotherapeutics based on FIT Biotech's proprietary Gene Transport Unit (GTU) technology for transient in vivo expression of monoclonal antibodies.
The agreement provides KU Leuven with an exclusive worldwide license to six undisclosed proprietary antibodies or marketed recombinant products.
“FIT Biotech continues to apply its platform technology in several therapeutic areas through collaborations and its own research and business development,” said Kalevi Reijonen, CEO and President, FIT Biotech Ltd.
Reijonen continued, “This agreement reflects our strategy to maximize the value of our technology by partnering with companies or universities that have a unique expertise to drive the development of promising vaccines or immunotherapeutics.”
“We are extremely delighted to collaborate with FIT Biotech and build further on their powerful technology platform,” said Nick Geukens, Research Manager of PharmAbs, the KU Leuven antibody center.
Geukens continued, “Our R&D program meets the clear need for more selective and effective management strategies to combat nosocomial infections and cancer. By commercializing our R&D programs we ultimately aim to establish a new, fully-dedicated Flemish spin-off company that will be responsible for (pre)clinical development and marketing of the generated products.”
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE